BioCardia, Inc.

    Jurisdiction
    United States
    LEI
    5493003EDBXRQRW22O75
    ISIN
    US09060U5074 (BCDA)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Read full profile

    Fundamentals

    Net revenue
    -€49.47K
    Gross margin
    369.0%
    EBIT
    -€5.23M
    EBIT margin
    10,565.5%
    Net income
    -€7.50M
    Net margin
    15,162.1%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Altman Peter President and CEO +700 $1.83 +$1.28K
    Altman Peter President and CEO +100 $1.83 +$183.00
    Altman Peter President and CEO +400 $1.75 +$700.00
    Altman Peter President and CEO +1.7K $1.76 +$2.99K

    Earnings Calls

    Earnings Calls

    Latest earnings call: May 14, 2024 (Q1 2024)

    Add to watchlist

    Notifications